Published in Vaccine Weekly, February 27th, 1995
The presentation, entitled Active Specific Immunotherapy of Adenocarcinomas Using Cancer-Associated Antigens was made at the Second Annual New Advances in Vaccine Technologies & Applications conference in Bethesda, Maryland.
As noted in the presentation, more than 50 percent of the patients studied are still alive in both the breast and ovarian groups, thus median survival time, in these late stage patients, is not yet available. The current breast and ovarian survival data, although preliminary, when tracked...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly